Alveus registers Phase 2 trial of ALV-100 for weight-loss maintenance after semaglutide
Alveus Therapeutics is recruiting for a Phase 2 dose-ranging study testing whether ALV-100 can sustain weight loss in patients who previously lost weight on semaglutide.
Alveus Therapeutics has one active registry entry this week, a Phase 2 study of its investigational drug ALV-100.
- ALV-100, a Phase 2 candidate for overweight and obesity, is recruiting under the study titled "A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously on Semaglutide"1, sponsored by Alveus Therapeutics. The trial enrolls participants who have a BMI of at least 27 kg/m2 and lost at least 10% of body weight while on semaglutide, with stable weight for at least 3 months before screening1. The study plans to enroll 220 participants1 and its primary outcome is the dose response of ALV-100 as measured by percentage change in body weight from baseline to Week 241.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.